A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

Publication Name: International Journal of Cancer

Author(s): C.A. Drukker, J.M. Bueno-de-Mesquita, V.P. Retèl, W.H. van Harten, H. van Tinteren, J. Wesseling, R.M.H. Roumen, M. Knauer, L.J. van ’t Veer, G.S. Sonke, E.J.T. Rutgers, M.J. van de Vijver, S.C. Linn

The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy-prognoSTics-in-breast-cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70-gene … Continued

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

Publication Name: EUROPEAN JOURNAL OF CANCER

Author(s): Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer

Background: The MINDACT (Microarray In Node-negative and 1–3 node positive Disease may Avoid ChemoTherapy) trial investigates the clinical utility of the 70-gene profile (MammaPrint) for the selection of breast cancer patients for adjuvant chemotherapy (CT) together with standard clinicopathological criteria. … Continued

First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations

Publication Name: Breast Cancer Res Treat

Author(s): Takayuki Iwamoto, Ju-Seog Lee. Giampaolo Bianchini, Rebekah E. Hubbard

The aims of this study were to compare the performance of six different genomic prognostic markers to predict long-term survival and chemotherapy response on the same patient cohort and assess if clinicopathological variables carry independent prognostic and predictive values. We … Continued

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue

Publication Name: PLOS ONE

Author(s): Lorenza Mittempergher, Jorma J. de Ronde, Marja Nieuwland, Ron M. Kerkhoven, Iris Simon,Emiel J. Th. Rutgers, Lodewyk F. A. Wessels, Laura J. Van't Veer

Background and Methods: Formalin Fixed Paraffin Embedded (FFPE) samples represent a valuable resource for cancer research. However, the discovery and development of new cancer biomarkers often requires fresh frozen (FF) samples. Recently, the Whole Genome (WG) DASL (cDNA-mediated Annealing, Selection, … Continued

TSPYL5 suppresses p53 levels and function by physical interaction with USP7

Publication Name: Nature Cell Biology

Author(s): Mirjam T. Epping, Lars A.T. Meijer, Oscar Krijgsman, Johannes L. Bos, Pier Paolo Pandolfi and René Bernards

We have previously reported a gene expression signature that is a powerful predictor of poor clinical outcome in breast cancer1. Among the seventy genes in this expression profile is a gene of unknown function: TSPYL5 (TSPY-like 5, also known as … Continued

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

Publication Name: The American Journal of Managed Care

Author(s): Er Chen, MPP; Kuo Bianchini Tong, MS; and Jennifer L. Malin, MD, PhD

Objective: To evaluate the cost-effectiveness of 70-gene MammaPrint signature (Agendia Inc, Huntington Beach, CA) vs Adjuvant! Online soft ware (AS) (http://www.adjuvantonline.com) in patients 60 years or younger with early-stage breast cancer. Study Design: Cost-effectiveness and cost-utility analyses from a US … Continued

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer

Publication Name: Biomarker Insights

Author(s): Sun Tian, Paul Roepman, Laura J van’t Veer, Rene Bernards, Femke de Snoo, and Annuska M Glas

Background: MammaPrint was developed as a diagnostic tool to predict risk of breast cancer metastasis using the expression of 70 genes. To better understand the tumor biology assessed by MammaPrint, we interpreted the biological functions of the 70-genes and showed … Continued

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

Publication Name: British Journal of Cancer

Author(s): M Knauer, F Cardoso, J Wesseling, PL Bedard, SC Linn, EJT Rutgers, and LJ van 't Veer

BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus … Continued

Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer

Publication Name: International Journal of Molecular Medicine

Author(s): Heidrun Gevensleben, Uwe-Jochen Gohring, Reinhard Buttner. Lukas C. Heukamp, Georg Kunz, Thomas Dimpfl, Christian Jackisch, Olaf Ortmann, Ute-Susann Albert, Richard Bender, Femke De Snoo, Oscar Krijgsman, Annuska M. Glas

The 70-gene expression profile MammaPrint is a powerful prognostic indicator for disease outcome in breast cancer patients with improved prediction of recurrence risk compared to currently used guidelines. The microarray-based test TargetPrint further provides reliable, quantitative assessment of mRNA expression … Continued

Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population

Publication Name: Japanese Journal of Clinical Oncology

Author(s): Makoto Ishitobi, Teodora Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska Glas, Ellen van Lienen, Hideo Inaji Laura van’t Veer and Kikuya Kato

Objective: van’t Veer and colleagues developed a 70-gene prognosis profile known as MammaPrint to identify breast cancer patients who were at low risk of developing metastases. We evaluated the prognostic value of the 70-gene MammaPrint profile in Japanese women with … Continued